Regenerative medicines have the potential to have a significant economic impact on the NHS in its long-term. In responding to the House of Commons Science and Technology Committee Inquiry into regenerative medicine, the Government has offered to try and create an integrated environment to support a world-leading regenerative medicine industry within the UK. It is committed to supporting the development of safe and effective new therapies, an environment that supports the provision of these therapies within the healthcare system and an Industrial Strategy that promotes the growth of the life sciences sector. It says the benefits that these therapies have long promised are now much closer to being realised with potentially transformative therapies in late-stage clinical trials.
The government has also backed other related activities including the 100,000 Genomes Project with the ambition for the UK to continue as a world-leader in the field. There are currently 13 Genomic Medicines Centres (GMCs) in England.